Getting better value from the NHS drug budget.

BMJ (Clinical research ed.)

Volumn 341, Issue , 2010, Pages

  Moon, James C ^a   Flett, Andrew S ^b   Godman, Brian B ^b   Grosso, Anthony M ^b   Wierzbicki, Anthony S ^b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; PRESCRIPTION DRUG; SIMVASTATIN;

ARTICLE; BUDGET; CLINICAL PRACTICE; ECONOMICS; HEALTH CARE POLICY; HEART FAILURE; HUMAN; HYPERTENSION; NATIONAL HEALTH SERVICE; PATENT; UNITED KINGDOM;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BUDGETS; DRUGS, GENERIC; GREAT BRITAIN; HEALTH CARE REFORM; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; LOSARTAN; PATENTS AS TOPIC; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTION DRUGS; SIMVASTATIN; STATE MEDICINE;

EID: 79551645071     PISSN: None     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.c6449     Document Type: Article

References (0)